Parry-Romberg Syndrome Market Research Report - Forecast Till 2030

Parry-Romberg Syndrome Market Information: By Diagnosis (Physical Examination, MRI Scan, Serum Test, and others), By Treatment (Drug Treatment, Surgery, others), and By End User (Hospitals & Clinics, Physical Therapists, others) - Forecast till 2030

ID: MRFR/Pharma/2986-HCR | January 2023 | Region: Global | 115 Pages         

Parry-Romberg Syndrome Market Speak to Analyst Request a Free Sample

Parry-Romberg Syndrome Market Scenario 


The Parry-Romberg Syndrome Market is expected to reach USD 923.3 Million by 2030 at 9.6% CAGR during the forecast period 2022-2030. Parry-Romberg syndrome is also known as progressive hemifacial atrophy. It is a rare disease, which is characterized by the shrinking and degeneration of the tissues beneath the skin. The changes and deterioration spread slowly and it occurs on one side and rarely extends to other parts of the body. General symptoms, includes facial changes, which involves the tissues above the upper jaw or between the nose and the upper corner of the lip and subsequently progress to the mouth, areas around the eye, the ear, and the neck. Currently, no cure and treatments are available for the parry-Romberg syndrome.


Increasing prevalence of skin diseases, neurological abnormalities, and eye defects are the major driving factors for the growth of the market during the forecast period. Moreover, oral diseases also boost the market growth as the tissues of mouth, including the tongue, gingiva, teeth, and soft palate are commonly involved in Parry-Romberg syndrome.

According to the Centers for Disease Control And Prevention, skin diseases is the most common in the US and over 7% of skin related diseases that are tracked by skin cancer registries are adding fuel to the market growth.  

According to the WHO, millions of people worldwide are affected by neurological abnormalities or disorder. More than 6 million people die because of stroke each year; over 80% of deaths take place in low and middle income countries, which will boost the market growth in developing regions.

On the other hand, high cost of current treatment methods, and long duration for complete cure, for instance, it takes one-two years for facial growth and after facial growth the surgery is proceeded, which may hamper the market growth.   


Parry-Romberg Syndrome Market Segmentation    


The global Parry-Romberg syndrome market is segmented on the basis of diagnosis, treatment, and end user.

On the basis of diagnosis, the market is segmented into physical examination, MRI, serum test, and other.

On the basis of treatment, the market is categorized into drug treatment, surgery, and others. The drug treatment is further segmented into methotrexate, corticosteroids, cyclophosphamide, azathioprine, and others. The surgery is sub-segmented into orthognathic surgery, microsurgical reconstructive surgery, and others.

On the basis of end user, the market is segmented into hospitals & clinics, physical therapists, and others.

Parry-Romberg Syndrome Market Key Players                                                                                   

Some of the key players in parry-romberg syndrome market are DePuy Synthes (U.S.), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), Abbott (US), Immediate Media Company Ltd. (US), Taj Pharmaceuticals Ltd.,  Pfizer, Inc., Sanofi-Aventis, Biogen, Inc., GlaxoSmithKline, Inc., and AstraZeneca plc.

Figure: Global Parry-Romberg Syndrome Market, by Region, 2016 (%) Parry-Romberg Syndrome Market-

Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation

 

Parry-Romberg Syndrome Market Regional Analysis 


The Americas dominates the global Parry-Romberg syndrome market owing to the presence of huge geriatric population, increasing number of patient with neurological disorder, eye related disorders. Moreover, high healthcare speeding, advanced hospitals infrastructures, availability of skilled healthcare professional are boosting the growth of the market.

Europe accounts for the second largest Parry-Romberg syndrome market across the globe owing to increasing government support for research & development, and increasing investment in healthcare. The countries such as France, and Germany investing in the healthcare to develop new diagnosis and treatment methods for rare diseases, which will boost the market growth. As per Organization for Economic Co-operation and Development (OECD), the share of GDP to health spending in Germany was 11.0% in 2013, compared with a share of GDP was up from 10.8% in 2012, which is responsible for the growth of the market in this region.

Asia Pacific has the fastest growing market, increasing government support for research & development, increasing prevalence of skin diseases, eye related diseases, and huge population base and rapidly developing economy drives the growth of the market in this region. Developing countries in this region are focusing more in the development of healthcare domain for instance country such as India.

The Middle East & Africa is expected to show the least market share due to less availability of medical facilities, and less development in healthcare domain.


Intended Audience



  • Pharmaceutical Companies

  • Medical Devices Manufacturer

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors




Research Methodology 





Parry-Romberg Syndrome Market Source: World Health Organization, Centers for Disease Control and Prevention, expert interview market research future analysis, annual report, white paper, company presentation



Report Scope:

Report Attribute/Metric Details
  Market Size   USD 923.3 Million
  CAGR   9.6%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Diagnosis, Treatment and End User
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   DePuy Synthes (U.S.), Johnson & Johnson Services, Inc. (US), Medtronic (Ireland), Abbott (US), Immediate Media Company Ltd. (US), Taj Pharmaceuticals Ltd., Pfizer, Inc., Sanofi-Aventis, Biogen, Inc., GlaxoSmithKline, Inc., and AstraZeneca plc.
  Key Market Opportunities

  • The Americas dominates the global Parry-Romberg syndrome market owing to the presence of huge geriatric population, increasing number of patient with neurological disorder, eye related disorders.
  • In Europe Region, Increasing government support for research & development, and increasing investment in healthcare
  • In Asia Pacific, increasing government support for research & development, increasing prevalence of skin diseases, eye related diseases, and huge population base and rapidly developing economy drives the growth of the market

    •   Key Market Drivers

  • Increasing prevalence of cancer
  • Increasing investment of biotechnology and pharmaceutical industries in R&D, Rising need for the better diagnostic methods

    		•


    Speak to Analyst Ask for Customization

    Frequently Asked Questions (FAQ) :

    Parry-Romberg syndrome market is expected to register 9.6% CAGR from 2022 to 2030.

    Parry-Romberg syndrome market is driven by rising incidence of skin conditions, neurological disorders, and eye defects.

    Long waiting times for cures and high costs for treatments are factors which can hamper the global Parry-Romberg syndrome market.

    The Americas can dominate the global Parry-Romberg syndrome market till 2030.

    Medtronic, Johnson & Johnson Services, Inc., AstraZeneca plc Biogen, Inc., Pfizer, Inc., Sanofi-Aventis, DePuy Synthes, GlaxoSmithKline, Inc., Taj Pharmaceuticals Ltd., Abbott, and Immediate Media Company Ltd. are major players of the global Parry-Romberg syndrome market.